CLINICAL TRIALS PROFILE FOR LINEZOLID

505(b)(2) Clinical Trials for LINEZOLID

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01734694 ↗	Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients	Terminated	Henry Ford Health System	Phase 4	2011-10-01	For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
New Dosage	NCT02778828 ↗	Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis	Completed	Groupe Hospitalier Paris Saint Joseph	N/A	2015-11-04	Linezolid, primary treatment for MDR-TB combination therapy anti. Until it is the dose of 600 mg x1 / day, rather sensible for most patients is more, which was unanimous. It is true that if a dosage is consensus, it goes without saying, because of the interindividual variability, marked moreover to linezolid, a therapeutic monitoring assay of plasma levels is indispensable for most pharmacological treatments. This therapeutic drug monitoring (TDM) often gives rise, as known, to dosage changes. It turns out that at present no real STP on the basic objectives PK / PD is really made in France in the treatment of tuberculosis (TB) and the bibliography remains rather poor recommendations, and yet all the elements are there: indeed linezolid is an antibiotic whose activity is purely "time-dependent". So one should fulfill 2 PK / PD objectives whose precise boundaries are sometimes still to be determined: -% T> MIC, or percentage of time spent with plasma concentrations above the minimum inhibitory concentration of linezolid (LNZ) for Mycobacterium tuberculosis. In practice, the residual concentration before the next shot must be> MIC (0.125 to 1 mg / l) - A fortiori it must also take into account the concentration preventing the appearance of resistant mutants, amounting to 1.2 mg / l - AUC / MIC> 80, or ratio of the area under the curve (AUC, Area under curve) of plasma concentration versus time and CMI LNZ Until then, and without real bibliographic support, and for the sake of kindness to patients coupled with an economic advantage, the STP consisted of 2 samples, a peak 1:30 after taking (Cmax) and a residual before taking (C min) , after all, to 600mg x1 / 24 correlates well with the AUC (55% peak and 75% for the residual). Following an observation that 25 to 30% of patients had a C min
New Indication	NCT05069974 ↗	Alternative Antibiotics for Syphilis	Recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 3	2021-10-01	The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent. It is estimated to include 360 participants.

All Clinical Trials for LINEZOLID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035269 ↗	New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)	Completed	Pfizer	Phase 3	2001-12-01	This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
NCT00035425 ↗	Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection	Completed	Pfizer	Phase 3	2001-11-01	This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
NCT00035854 ↗	New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)	Completed	Pfizer	Phase 3	2002-02-01	This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
NCT00037050 ↗	Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria	Completed	Pfizer	Phase 3	2002-04-01	This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00084266 ↗	Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)	Completed	Pfizer	Phase 4	2004-10-01	To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.

Clinical Trial Conditions for LINEZOLID

Condition Name

Condition Name for LINEZOLID
Intervention	Trials
Tuberculosis	15
Pulmonary Tuberculosis	12
Tuberculosis, Multidrug-Resistant	9
Gram-Positive Bacterial Infections	9

Condition MeSH

Condition MeSH for LINEZOLID
Intervention	Trials
Infections	46
Tuberculosis	46
Infection	44
Communicable Diseases	40

Clinical Trial Locations for LINEZOLID

Trials by Country

Trials by Country for LINEZOLID
Location	Trials
United States	438
China	126
South Africa	70
Japan	42
Brazil	29

Trials by US State

Trials by US State for LINEZOLID
Location	Trials
California	32
Texas	26
Ohio	24
Georgia	23
Florida	22

Clinical Trial Progress for LINEZOLID

Clinical Trial Phase

Clinical Trial Phase for LINEZOLID
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	5
PHASE2	2

Clinical Trial Status

Clinical Trial Status for LINEZOLID
Clinical Trial Phase	Trials
Completed	75
Recruiting	31
Not yet recruiting	15

Clinical Trial Sponsors for LINEZOLID

Sponsor Name

Sponsor Name for LINEZOLID
Sponsor	Trials
Pfizer	30
Beijing Chest Hospital	9
National Institute of Allergy and Infectious Diseases (NIAID)	8

Sponsor Type

Sponsor Type for LINEZOLID
Sponsor	Trials
Other	318
Industry	91
NIH	10

LINEZOLID Market Analysis and Financial Projection

Last updated: April 24, 2026

Linezolid (Antibacterial) Clinical Trials Update and Market Outlook: Where Activity Is Concentrated and How Forecasts Typically Shape Pricing

What is the current clinical-trials picture for linezolid?

Linezolid is a long-established oxazolidinone antibacterial. Most development focus in recent years has shifted from first-line innovation to (1) new formulations (bioavailability, patient handling), (2) combination and salvage-use studies in specific settings, and (3) expanded evidence in resistant gram-positive infections where linezolid is a backbone option.

Key trial themes observed in current activity (by target clinical questions):

• Dose- and exposure-related optimization (weight-based dosing, pharmacokinetic/pharmacodynamic targets)
• Switch therapy evidence (IV-to-oral sequencing in defined clinical pathways)
• Resistance and complicated infection subsets (MRSA, diabetic foot infection, nosocomial settings)
• Safety monitoring and tolerability endpoints (myelosuppression, thrombocytopenia, neuropathy, lactic acidosis in prolonged use)

Implication for R&D and BD: When a molecule is mature and widely used, trial volume tends to concentrate in narrow clinical segments and product-specific regulatory packages (formulation, route, and regimen). Competitive advantage is therefore more tied to regulatory strategy and patient-utility endpoints than to new mechanism differentiation.

What market forces define linezolid demand and pricing power?

Linezolid competes in gram-positive infections against:

• Glycopeptides (vancomycin, teicoplanin where available)
• Lipopeptides (daptomycin)
• Broad cephalosporins and newer cephalosporin/beta-lactam combinations in selected MSSA/streptococcal contexts
• Newer anti-MRSA agents in hospitals with formulary control

Demand drivers that typically support linezolid utilization:

• High clinical value in MRSA and suspected/confirmed resistant gram-positive infections
• Oral availability enables earlier discharge and outpatient continuation in many formularies
• Strong fit in complicated skin and skin structure infections and hospital-acquired pneumonia decision pathways

Pricing and access constraints:

• Strong generic penetration in many markets reduces price floors
• Hospitals apply antibiotic stewardship and restrict linezolid to guideline-consistent indications and resistance patterns
• Payors increasingly tie reimbursement to approved labeled indications and local treatment pathways

Where is linezolid market activity concentrated by region and setting?

Linezolid demand is generally strongest where:

• MRSA and resistant gram-positive infection rates are high
• Hospital formularies favor early targeted therapy
• Patients can access oral therapy for step-down treatment
• Stewardship frameworks use linezolid as a practical alternative when beta-lactam coverage is uncertain

Setting concentration:

• Inpatient: severe MRSA, pneumonia, complicated infections needing IV start
• Step-down: oral linezolid after stabilization
• Specialty pathways: infectious disease and stewardship-driven protocols

How do projections typically look for linezolid (volume, value, and share)?

Because linezolid is mature and largely commoditized via generics in many geographies, most forward-looking projections show:

• Stable to modest growth in global volume, driven by infection burden and oral switch practices
• Flat-to-declining real pricing as generics consolidate
• Value movement tied to mix (IV vs oral, hospital procurement cycles) rather than unit price expansion

Practical investment lens: For linezolid, market-outlook upside most often comes from:

• Formulation lifecycle management (new registrants in specific markets)
• Regulatory expansion of dosing/regimens that reduce hospitalization cost or improve compliance
• Hospital contract wins where switching policies favor oral step-down or standardized protocols

What is the competitive and patent context that shapes commercialization?

Linezolid’s origin is long past modern patent cliffs, and the market is dominated by generics. Commercial differentiation tends to be:

• Bioequivalence and stability (product quality and shelf-life)
• Handling (IV infusion convenience, oral tablet scoring, suspension/alternative formats where approved)
• Regulatory leverage (expedited generic pathways plus lifecycle extensions in specific jurisdictions)

What this means for market projections: forecasts are less sensitive to mechanism breakthroughs and more sensitive to:

• Regulatory access in target countries
• Hospital procurement practices and national tender structures
• Stewardship and guideline updates that either tighten or expand authorized use

Clinical trials update by development archetype

Linezolid development now most commonly falls into four buckets. Each influences market adoption differently:

1. New formulations

   • Goal: improved patient handling, reduced administration friction, better tolerability profile for real-world duration
   • Commercial impact: helps win procurement when pharmacy teams require practical administration and consistent supply

2. Regimen optimization / switch therapy

   • Goal: validate sequencing from IV to oral without compromising outcomes in defined patient profiles
   • Commercial impact: drives length-of-stay reduction and supports outpatient continuation, which often matters to payors

3. Indication expansion within gram-positive niches

   • Goal: reinforce use in complicated infections or special populations where guideline evidence is still evolving
   • Commercial impact: can change formulary placement, but magnitude depends on local guideline adherence

4. Real-world safety evidence

   • Goal: refine risk mitigation for long courses and specific at-risk groups (older patients, prolonged therapy)
   • Commercial impact: supports stewardship confidence and reduces reluctance among prescribers

Market analysis snapshot: what typically determines share movement

Given generic competition, share movement often follows these levers:

• Tender pricing: biggest driver in many public procurement systems
• Supply reliability: second-order driver that can override minor clinical differences
• Stewardship alignment: products that fit approved protocols gain preference
• Availability of oral step-down: supports clinical pathway adoption

Forecast structure for business planning (how to model linezolid)

For linezolid, a defensible planning model usually decomposes market value into:

• Incidence and severity mix for MRSA/complicated gram-positive infections
• Treatment pathway share (IV initiation rate, switch to oral rate)
• Generics pricing curve by region (tender and competition effects)
• Compliance to labeled indications (steering and stewardship)
• Capacity and supply constraints (contract execution risk)

Outcome expectation: Even if clinical need remains consistent, the global value pool tends to grow slower than infection incidence because pricing compresses under generic competition.

What does the evidence base suggest about where clinical value remains strongest?

Linezolid continues to hold value where it:

• Provides reliable activity against resistant gram-positive pathogens
• Fits oral-to-IV sequencing in real-world care
• Serves as an effective option when alternatives are constrained by allergy profiles, renal toxicity concerns, or localized resistance patterns

These characteristics keep linezolid relevant even as new antibiotics enter the market.

---

Key Takeaways

• Linezolid’s current clinical activity is mainly about formulation, regimen sequencing, and niche evidence rather than new mechanism breakthroughs.
• Market growth is typically volume-led with pricing compression under generic competition.
• Share gains are usually driven by tender execution, stewardship alignment, and oral switch pathway fit, not by novel clinical efficacy claims.
• Forward projections should be modeled using pathway adoption rates (IV-to-oral), labeled indication adherence, and regional tender dynamics.

---

FAQs

1) Is linezolid still used for MRSA and serious gram-positive infections?

Yes. Clinical use remains anchored in resistant gram-positive infections, especially where targeted therapy and oral step-down support stewardship-driven protocols.

2) What type of linezolid clinical trials are most common now?

Trials most often address formulation performance, IV-to-oral switch regimens, and evidence in specific complicated infection populations, with safety monitoring as a core endpoint.

3) How do generics affect linezolid market forecasts?

They typically compress real pricing, so forecasts usually show slower value growth than volume growth, with value changes driven by mix shifts (IV vs oral) and procurement outcomes.

4) What drives hospital adoption of a specific linezolid product?

Procurement pricing, reliable supply, ease of administration, and fit to approved stewardship pathways (including step-down practices) drive adoption.

5) What are the main risks in a linezolid market outlook model?

Key risks are tender price competition, stewardship restriction changes, and supply execution risk, which can swing realized revenues even if clinical demand is stable.

---

References

[1] FDA. Drug Approval Package for Zyvox (linezolid). U.S. Food and Drug Administration.
[2] EMA. Zyvox and related linezolid product assessment history. European Medicines Agency.
[3] World Health Organization. WHO Model List of Essential Medicines: Antimicrobial Agents (linezolid included in relevant contexts). World Health Organization.
[4] PubMed. Linezolid clinical studies (trial records covering formulation, switch therapy, and safety endpoints). U.S. National Library of Medicine.